Intellia Therapeutics, Inc. (NTLA) key performance indicators and operating metrics (3 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Collaboration Revenue | 15.05M | FY2026-Q1 |
| Expected Total Patients Enrolled in the Phase 3 Magnitude Trial by Year End | 650.00 | FY2025-Q2 |
| Number of Patients Who Received a One-Time Dose of 0.3 Milligrams per Kilogram or Higher | 33.00 | FY2025-Q3 |
Back to NTLA overview · NTLA earnings · NTLA holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.